October 2016 Europe Supplement - Endovascular Today

Table of Contents

European Supplement

October 2016 Europe Supplement

RevELUTIONizing Drug-Eluting Technologies

How drug-eluting therapies are shaping a new era of endovascular interventions.

Sponsored by Boston Scientific Corporation

Issue

SFA Intervention: The Next Level

Considerations on tomorrow's effectiveness benchmarks.

View Issue

Download PDF

Complexity of SFA Disease Is Driving the Need for Dual Therapy

A discussion of potential differential indications for drug-eluting devices.

By Prof. Thomas Zeller, MD

The Future of Antiproliferative Therapies for Endovascular Interventions

Translational findings from the Ranger Paclitaxel-Coated Balloon data.

By Renu Virmani, MD, FACC

The Science Behind Local Drug-Delivery Technologies: The Benefit of Sustained Paclitaxel Release in the SFA

Sustained drug release is key to maintaining biological effect.

By Juan F. Granada, MD, FACC

Patterns of Restenosis: What Are the Data Telling Us?

With Michael R. Jaff, DO

Ranger Paclitaxel-Coated PTA Balloon Catheter Clinical Update

Recent early data from two studies demonstrate the promise of the Ranger DCB.

Sustained Drug Release Optimizes Long-Term Outcomes

Is the drug-eluting vascular stent a game-changer?

By Prof. Stefan Müller-Hülsbeck, MD, EBIR, FCIRSE, FICA

Are DCBs a Durable Solution?

A discussion of DCB durability and superiority in the context of 2-year data.

By Gary M. Ansel, MD

The Future of Drug-Eluting Therapies: What Will the Treatment Algorithm Look Like?

By William A. Gray, MD

Global Perspectives on Drug-Eluting Technologies

With Prof. Thomas Zeller, MD; Antonio Micari, MD, PhD; Konstantinos Katsanos, MSc, MD, PhD, EBIR; and Yann Gouëffic, MD, PhD

Latest Issues

May 2026

April 2026

March 2026

February 2026

January 2026

View All Issues